|
Jan 9
|
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
|
|
Dec 27
|
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
|
|
Dec 21
|
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
|
|
Dec 4
|
SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia
|
|
Nov 29
|
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
|
|
Jul 15
|
Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely
|
|
Apr 26
|
SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
|